TABLE 1.
Clinical characteristics of patients with LRSA
| Patient no. | Isolate | Collection date (mo/yr) | Sex | Age (yr) | Days of LRSA isolation/no. of days in ICU | Antibiotic therapy within 2 wk prior to LRSA isolationa | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | LRSA417 | 4/2013 | Male | 66 | 16/50 | TZP | Survived |
| 2 | LRSA422 | 4/2013 | Male | 65 | 3/13 | None | Died |
| 3 | LRSA531 | 5/2013 | Male | 63 | 9/26 | CMN, TZP | Survived |
| 4 | LRSA608 | 6/2013 | Female | 61 | 22/28 | MOX, MEM, TEC | Survived |
| 5 | LRSA621 | 6/2013 | Male | 40 | 15/22 | MEM, TZP, AK | Survived |
| 6 | LRSA726 | 7/2013 | Male | 45 | 33/58 | AK, MEM, PB | Died |
a
TZP, piperacillin-tazobactam; CMN, cefminox; MOX, moxifloxacin; MEM, meropenem; TEC, teicoplanin; AK, amikacin; PB, polymyxin B.